Medical Xpress

APRIL 25, 2023

Researchers at National Jewish Health have found that a subset of children suffering recurring fevers as a result of long COVID-19 have benefited from a daily medication treatment commonly used for gout and periodic fever syndrome. The case study is published in The Journal of Allergy and Clinical Immunology: In Practice.

Research 98

Research Allergies Drugs 98

Scienmag

MAY 18, 2022

LA JOLLA, CA—The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is sponsoring a major new antiviral drug development center that will be led by Scripps Research.

Allergies 90

Allergies Research Development Drugs 90

Drug Discovery World

JUNE 30, 2023

Whether it be a monoclonal antibody to treat peanut allergy, or using artificial intelligence (AI) to identify influenza drug targets, each discovery reflects the level of scientific innovation and diversity of approaches being employed in drug development today. The top stories: Could a monoclonal antibody treat peanut allergy?

Allergies 52

Allergies Drugs Antibody Regulation 52

Pharmaceutical Technology

JUNE 28, 2022

Researchers at the Rensselaer Polytechnic Institute in the US have received a five-year, $3.5m grant from the National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) for developing a Covid-19 oral antiviral drug. Meanwhile, the NIH also granted a $2.7m

Development 147

Development Bioinformatics Drugs Allergies 147

The Pharma Data

JANUARY 7, 2021

This clearance is a pivotal regulatory milestone that further supports Camallergy’s leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy,” said Sherden Timmins, Chief Technology Officer. 8, 2021 07:00 UTC. About Camallergy.

Allergies 52

Allergies Manufacturing Production Clinical Trials 52

BioTech 365

OCTOBER 7, 2020

LONDON–(BUSINESS WIRE)–#AllergyRhinitisDrugsMarket–The global allergy rhinitis drugs market size is poised to grow by USD 2.4 billion during 2020-2024, progressing at a CAGR of almost 4% throughout the forecast period, according to the latest report by Technavio.

Allergies 40

Allergies Marketing Drugs Research 40

Drug Discovery World

JANUARY 12, 2024

This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. The post This week in drug discovery (8-12 January) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Immune Response Allergies Bacteria 52

XTalks

JUNE 23, 2023

The American Medical Association (AMA) recently announced the recipients of the 2023 Electronic Health Record (EHR) Use Research Grant Program. Nine organizations will receive a total of $589,000 for research focused on studying the use of EHR systems.

Research 96

Research Allergies Medicine Pharmacy 96

Scienmag

MARCH 19, 2021

Most drugs operate via the membranes that surround the body’s cells. A study by researchers at Karolinska Institutet in Sweden has now mapped the structure and mechanism of MGST2, a membrane enzyme that, amongst other things, plays a part in chronic inflammation and cancer.

Research 74

Research Drugs Allergies Medicine 74

Camargo

NOVEMBER 24, 2020

Most are familiar with, know someone who uses, or take “pumps” themselves to prevent or relieve shortness of breath after an effort or during allergy season. Interest in the pulmonary route has also grown in recent years because delivering the drugs through the lungs allows direct systemic delivery and bypasses the first pass metabolism.

Drug Delivery 130

Drug Delivery Drugs Allergies Medicine 130

Drug Discovery World

AUGUST 5, 2022

Research paves way for easier brain tumour diagnosis. New research could pave the way to the earlier diagnosis of brain tumours through the development of a simple blood test for glioblastomas. International researchers win £30m for work in treating heart conditions. DDW partners with ELRIG at Drug Discovery 2022.

Drugs 52

Drugs Allergies Scientist Research 52

Trialfacts

JULY 5, 2022

Researchers are exploring a potential cancer treatment. Researchers are inviting healthy males to join this paid clinical trial. If you are generally healthy and want to advance medical research, consider joining! Participants may help researchers further develop cancer treatments. Why Participate? . Why Participate? .

Research 52

Research Clinical Research Allergies Clinical Trials 52

Drug Discovery World

OCTOBER 21, 2022

However, there was also controversy as researchers faced a backlash from the National Institute of Allergy and Infectious Diseases for their study which created a hybrid version of Covid-19. . Boston researchers criticised over creation of Covid-19 variant . Cancer drug shows promise in treating incurable lung disease .

Drugs 52

Drugs Allergies Clinical Trials Clinical Trials 52

Scienmag

OCTOBER 29, 2020

A key step in the immune system’s response to allergens has been uncovered by researchers at Massachusetts General Hospital. BOSTON – A key step in the immune system’s response to allergens has been uncovered by researchers at Massachusetts General Hospital (MGH).

Allergies 57

Allergies Development Drugs Research 57

Trialfacts

JUNE 16, 2022

Research Center: PAREXEL Baltimore Early Phase Clinical Unit. Lead Researcher: Ronald Goldwater, M.D. Researchers at PAREXEL Baltimore Early Phase Clinical Unit are conducting a study that invites generally healthy individuals to participate! Participants will be helping to advance medical research. About the Study.

Research 52

Research Allergies FDA Approval Drugs 52

Drug Discovery World

MAY 17, 2023

A first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body has begun. The trial is testing the safety, tolerability and processing in the body of escalating doses of the investigational drug product HOPO 14-1 in healthy adults.

Contamination 52

Contamination Trials Drugs Allergies 52

World of DTC Marketing

OCTOBER 6, 2021

to produce, according to a report issued last week by drug pricing experts at the Harvard School of Public Health and King’s College Hospital in London. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, also provided Emory with more than $19 million in additional grants.

Clinical Trials 198

Clinical Trials Clinical Trials Allergies Trials 198

XTalks

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has granted expanded approval to Genentech’s (part of Roche) Xolair (omalizumab) to help reduce allergic reactions to various foods after accidental exposure. The class of IgE-mediated food allergies includes 160 foods, with peanuts, milk, eggs, wheat, soy and tree nuts being the most common ones.

Allergies 100

Allergies FDA Approval Drugs Protein 100

Drug Discovery World

JULY 3, 2023

Whether it be a monoclonal antibody to treat peanut allergy, or using artificial intelligence (AI) to identify influenza drug targets, each discovery reflects the level of scientific innovation and diversity of approaches being employed in drug development today.

Allergies 52

Allergies Antibody Drugs Development 52

Trialfacts

DECEMBER 6, 2023

More Study Details About the Research Center: Location Research Center: Icahn School of Medicine at Mount Sinai Location: 1399 Park Avenue, New York, New York, 10029-6574, United States Lead Researcher: James Murrough, M.D., Participants will be helping to advance medical research. Your Rights Who Can Participate?

Research 52

Research Medicine Allergies Development 52

Delveinsight

AUGUST 6, 2020

TSHA-101, a potential treatment for GM2 gangliosidosis, is set to be the first drug to enter the clinic. FDA turns back peanut allergy patch of DBV Technologies. A peanut allergy patch which is based on new delivery technology has hit a snag at the FDA. The agency raised no safety concerns.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

Scienmag

SEPTEMBER 4, 2020

Anticholinergic medications are used for many conditions but might also accelerate cognitive decline, especially in older persons with biological or genetic risk factors A team of scientists, led by researchers at University of California San Diego School of Medicine, report that a class of drugs used for a broad array of conditions, from allergies (..)

Allergies 41

Allergies Drugs Genetics Scientist 41

Drug Discovery World

OCTOBER 21, 2022

A research team from Boston University has caused controversy for work involving the creation of a hybrid SARS-CoV-2 virus. . A range of media outlets pointed to the fact that the researchers’ chimeric virus – labelled Omi-S – was especially lethal to lab mice, killing around 80% of those it was tested in.

Research 52

Research Protein Allergies Development 52

FDA Law Blog

OCTOBER 10, 2023

has joined the firm as a Principal Drug Regulatory Expert. Dr. Beitz served in leadership positions in FDA’s Center for Drug Evaluation and Research for nearly three decades. (“HP&M”), the largest FDA-dedicated law firm, is pleased to announce that Julie Beitz, M.D.

Drugs 49

Drugs Dermatology Production Allergies 49

Scienmag

JANUARY 14, 2021

Newly identified pathway explains why antihistamine drugs often don’t work to control severe itch Credit: Illustration by Madison Mack In addition to a skin rash, many eczema sufferers also experience chronic itching, but sometimes that itching can become torturous. New research […].

Allergies 57

Allergies Drugs Research Dermatology 57

The Pharma Data

APRIL 26, 2022

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, according to a new study by researchers at the Indian Institute of Science (IISc).

Protein 52

Protein Drugs Allergies FDA Approval 52

VirTrial

FEBRUARY 28, 2024

If you missed Signant’s February 2024 webinar about optimizing patient-reported outcomes measurement strategy throughout oncology drug development, we’ve summarized the key takeaways and provided a link for you to watch the recording. Watch the recording You can watch the recorded webinar here.

Development 52

Development Drugs Trials Clinical Development 52

Drug Discovery World

DECEMBER 13, 2023

The event will take place on 5 and 6 February 2024 at SLAS in Boston, and will present leading research from experts in academia, government agencies and industry on how technology is innovating from bench to bedside, lab to patient. Register now to show your interest. Register now to show your interest.

Allergies 52

Allergies Engineer Drugs Development 52

pharmaphorum

FEBRUARY 16, 2022

A woman with HIV who received a stem cell transplant to treat acute myeloid leukaemia (AML) appears to have been cured of the infection according to US researchers. The post Stem cell therapy ‘cures’ first woman with HIV, say researchers appeared first on. “This third case of HIV remission suggests that CCR?5/?32

Gene Editing 67

Gene Editing Research Gene Genetics 67

Drug Discovery World

JANUARY 16, 2024

Dr Masaru Kanekiyo On Tuesday 6 February at 11.30am, the speaker will be Masaru Kanekiyo, DVM, PhD, Investigator and Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH.

Vaccination 64

Vaccination Vaccine Allergies Protein 64

Clinical Trial Podcast

SEPTEMBER 26, 2022

When a new drug or device undergoes “first in human” experience, the primary focus is on participant safety. How will the drug or device interact with the human body? And will this interaction be safe? Dr. Cohen has more than 30 years of healthcare experience which includes his work on clinical development.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Clinical Research 98

Drug Discovery World

NOVEMBER 15, 2022

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. .

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

Drug Discovery World

NOVEMBER 24, 2022

The money was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The new contracts will support the development of promising antiviral candidates from late-stage preclinical studies through investigational new drug application-enabling activities and clinical testing. .

Development 52

Development Allergies Production Drugs 52

Drug Discovery World

DECEMBER 18, 2023

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID). The post Study suggests ways to improve future HIV vaccine candidates appeared first on Drug Discovery World (DDW).

Vaccination 59

Vaccination Vaccine Allergies Clinical Trials 59

Triage Cancer

NOVEMBER 4, 2021

million preventable adverse drug interactions every year in US hospitals and long-term care facilities. Medication errors in healthcare facilities include dispensing the wrong drug or the wrong dosage, drug overdoses, and overlooked drug interactions and allergies. Medication Issues at Home.

Nurses 97

Nurses Doctors Doctor Allergies 97

The Pharma Data

AUGUST 12, 2020

New research has warned that minority groups and people of colour are underrepresented in current trials for COVID-19 therapies, despite the disproportionately higher rates of infection, hospitalisation and death faced by these groups.

Research 52

Research Clinical Trials Clinical Trials Allergies 52

Pharmaceutical Technology

APRIL 26, 2023

Dr. Amy Chan, senior clinical research fellow at the School of Pharmacy, University of Auckland, says digital inhalers have existed for almost 30 years. However, researchers investigating electronic monitoring devices also found failure rates of 13–16%, indicating the importance of quality control.

Clinical Trials 289

Clinical Trials Clinical Trials Allergies Research 289